Seeking Alpha

Prana Biotechnology (PRAN +3.2%) moves up after being initiated at Burrill Institutional...

Prana Biotechnology (PRAN +3.2%) moves up after being initiated at Burrill Institutional Research with an Outperform and a price target of $5 a share. Burrill cites the company's progress in developing technology for the treatment of neurodegenerative disorders. Yesterday PRAN announced that it's completed recruitment in its Phase IIa clinical trial using its experimental drug PBT2 for the treatment of patients with Huntington Disease.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs